Selecting Patients for Exclusive Permanent Implant Prostate Brachytherapy: The Experience of the Paris Institut Curie/Cochin Hospital/Necker Hospital Group on 809 Patients

Journal Article · Tue Jul 15 00:00:00 EDT 2008 · International Journal of Radiation Oncology, Biology and Physics

DOI:https://doi.org/10.1016/j.ijrobp.2007.11.056· OSTI ID:21124349

Cosset, Jean-Marc ^[1]; Flam, Thierry ^[2]; Thiounn, Nicolas ^[3]; Gomme, Stephanie; Rosenwald, Jean-Claude; Asselain, Bernard; Pontvert, Dominique; Henni, Mehdi ^[1]; Debre, Bernard ^[2]; Chauveinc, Laurent ^[1]

---

1. Institut Curie, Paris (France)
2. Cochin Hospital, Paris (France)
3. Necker Hospital, Paris (France)

Purpose: The aim of this study was to analyze overall and relapse-free survival in a cohort of 809 patients, 34% of whom corresponded to a higher-risk group than American Brachytherapy Society (ABS) criteria. Methods and Materials: Between January 1999 and September 2004, 809 patients were treated with permanent loose 125 iodine seed implantation (IsoSeed Bebig, Eckert and Ziegler) by the Paris Institut Curie, Cochin Hospital, and Necker Hospital group. Of these 809 patients, 533 (65.9%) corresponded exactly to ABS criteria. Two hundred and seventy-six patients (34.1%) had a prostate-specific antigen (PSA) level between 10 and 15, or a Gleason score of 7, or both (non-ABS group). Results: Overall 5-year survival was 98%, with no difference between the ABS group and the non-ABS patient subgroups (p 0.62).Five-year relapse-free survival was 97% in the ABS group; it was significantly lower (p = 0.001) in the non-ABS group but remained satisfactory at 94%. On subgroup analysis, the results appeared to be better for the subgroup of patients with PSA 10-15 than for the subgroup with a Gleason score of 7. Conclusions: Our results suggest that selected patients in the intermediate-risk group of localized prostate cancers can be safely proposed as recipients of permanent implant brachytherapy as monotherapy.

• OSTI ID: 21124349
• Journal Information: International Journal of Radiation Oncology, Biology and Physics, Vol. 71, Issue 4; Other Information: DOI: 10.1016/j.ijrobp.2007.11.056; PII: S0360-3016(07)04691-3; Copyright (c) 2008 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
ANTIGENS
BRACHYTHERAPY
HOSPITALS
NEOPLASMS
PATIENTS
PROSTATE
RADIATION SOURCE IMPLANTS